March 22, 2024Cancer Research

Enhancing CAR-T Antitumor Efficacy with Secreted Anti-PD-1 and IL-21 Fusion Protein

View Full Paper

Ask AI

Bookmark

CAR-T cells engineered to secrete an anti-PD-1 and interleukin-21 fusion protein maintain proliferation under low IL-2 and achieve superior tumor clearance.
In vitro testing confirms STAT3 phosphorylation and enrichment of memory stem cells expressing TCF-1, CCR7, and CD62L, unlike standard effector CAR-T products.
Preclinical xenograft models of lymphoma, myeloma, and breast cancer demonstrate enhanced expansion; human clinical translation requires further validation.

Authors

YLYing LiWeifang Medical University JZJitao ZhaoTianjin University XCXiangrui ChengXi'an Jiaotong University

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Preclinical study demonstrates that anti-PD-1 and IL-21 fusion-secreting CAR-T cells enhance tumor eradication across cancer xenografts, highlighting a strategy to boost memory persistence.

Cite This Study

Li et al. (2024) studied this question.

synapsesocial.com/papers/68e72e24b6db6435876a76be https://doi.org/10.1158/1538-7445.am2024-3999

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study demonstrates that anti-PD-1 and IL-21 fusion-secreting CAR-T cells enhance tumor eradication across cancer xenografts, highlighting a strategy to boost memory persistence.

Enhancing CAR-T Antitumor Efficacy with Secreted Anti-PD-1 and IL-21 Fusion Protein

Key Points

Discussion

Implication

Cite This Study

Enhancing CAR-T Antitumor Efficacy with Secreted Anti-PD-1 and IL-21 Fusion Protein

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider